Overview

A Phase 1/2 Study Evaluating the Safety and Efficacy of CLBS201 in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Status:
Not yet recruiting
Trial end date:
2024-08-15
Target enrollment:
Participant gender:
Summary
CLBS201 will be studied to evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and Type 2 DM.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Caladrius Biosciences, Inc.